BIG EYE DIAGNOSTICS INC
San Diego, CA · Medtech · Private
Biplex lateral flow assay for onchocerciasis diagnosis with two novel O. volvulus antigens
- Grants
- $6.7M
- 11 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- $600K
- 2 awards · Health and Human S
- #372 of 4531 in medtech
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Ultrasensitive, High-Specificity Rapid Test to Support the End-Game of the Global Program to Eliminate Lymphatic Filariasis | $259,562 | |
| Federal grant | Department of Health and Human Services · Phase I · Ultrasensitive, High-Specificity Rapid Test to Support the End-Game of the Global Program to Eliminate Lymphatic Filariasis | $259,562 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · First-in-class, highly sensitive and specific rapid diagnostic test to detect Paragonimus infections | $258,171 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · First-in-class, highly sensitive and specific rapid diagnostic test to detect Paragonimus infections | $258,171 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Supporting Who Onchocerciasis Elimination Programs: Progressing A Highly Sensitive And Ultra-specific Rapid Diagnostic Test To Commercialization Readiness | $921,480 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Supporting Who Onchocerciasis Elimination Programs: Progressing A Highly Sensitive And Ultra-specific Rapid Diagnostic Test To Commercialization Readiness | $921,480 | |
| Federal grant | Department of Health and Human Services · Phase II · Supporting Who Onchocerciasis Elimination Programs: Progressing A Highly Sensitive And Ultra-specific Rapid Diagnostic Test To Commercialization Readiness | $908,264 | |
| Federal grant | Department of Health and Human Services · Phase II · Supporting WHO Lymphatic Filariasis Elimination Programs: Progressing a Highly Sensitive and Specific Rapid Diagnostic Test for Brugia Species Infection to Commercialization Readiness | $797,183 | |
| Federal grant | Department of Health and Human Services · Phase II · Ultrasensitive, High-Specificity Rapid Test to Support the End-Game of the Global Program to Eliminate Lymphatic Filariasis | $852,688 | |
| Federal contract | Department of Health and Human Services · An Easy-to-use, Low-cost Triplex Rdt For The Simultaneous Diagnosis Of Hbv, Hcv, And Hiv Infection, Compatible With Field Use In Lmics And At-home Use In The US | $299,659 | |
| Federal contract | Department of Health and Human Services · Novel Diagnostic Biomarkers Discovery And Validation For Malaria And Select Neglected Tropical Diseases SBIR Phase I | $299,986 | |
| Federal grant | Department of Health and Human Services · Phase II · Supporting WHO Lymphatic Filariasis Elimination Programs: Progressing a Highly Sensitive and Specific Rapid Diagnostic Test for Brugia Species Infection to Commercialization Readiness | $396,523 | |
| Federal grant | Department of Health and Human Services · Phase II · Ultrasensitive, High-Specificity Rapid Test to Support the End-Game of the Global Program to Eliminate Lymphatic Filariasis | $842,379 |
Federal grant · SBIR/STTRFederal contract · USAspending
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 369 | PGXL TECHNOLOGIES LLC | $606K | — |
| 370 | Ribomed Biotechnologies, Inc. | $603K | — |
| 371 | SONATA SCIENTIFIC LLC | $600K | — |
| 372 | BIG EYE DIAGNOSTICS INC | $600K | — |
| 373 | AO TECHNOLOGIES, LLC | $597K | — |
| 374 | HEMOSONICS | $576K | $25M |
| 375 | Maryland Development Center, LLC | $574K | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.